PMID: 9451424Feb 6, 1998Paper

Decreased expression of c-myc oncoprotein by peripheral blood mononuclear cells in thalassaemia patients receiving desferrioxamine

European Journal of Haematology
D KyriakouG D Eliopoulos

Abstract

Desferrioxamine (DFX) is an iron chelation agent widely used in the treatment of transfusional iron overload in patients with thalassaemia major and other severe refractory anaemias. DFX has been shown to induce inhibition of DNA synthesis and apoptosis in vitro; however, the molecular targets of DFX action are not well known. The c-myc proto-oncogene is involved in a number of cellular processes including proliferation, differentiation and apoptotic cell death. We have examined the expression of c-myc in peripheral blood mononuclear cells from 71 patients with homozygous beta-thalassaemia in regular transfusion and iron chelation therapy with DFX, 5 non-transfusion, non-chelation-dependent thalassaemic patients, and 15 healthy volunteers using an APAAP immunocytochemical method. We have found that mononuclear cells from thalassaemic patients receiving DFX express significantly lower levels of c-myc protein compared to control healthy volunteers or thalassaemics receiving no DFX. In vitro treatment of HL60 or K562 leukaemic cells with 100 microliters DFX also induced a rapid decrease in c-myc mRNA and protein levels, followed by apoptosis and inhibition of DNA synthesis. These effects were blocked by simultaneous addition of fe...Continue Reading

References

Aug 1, 1976·British Journal of Haematology·A V HoffbrandM H Tattersall
Mar 1, 1992·Clinical and Experimental Immunology·C PhilippeL Baud
Sep 1, 1992·British Journal of Haematology·K PattanapanyasatR C Hider
Sep 1, 1992·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·G J Kato, C V Dang
Apr 3, 1992·Cell·G I EvanD C Hancock
Mar 1, 1990·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·K SofroniadouJ Zervas
Jan 1, 1986·Annual Review of Genetics·M D Cole
Aug 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·H M LachmanC L Schildkraut
Feb 1, 1984·Annals of Internal Medicine·P GascónN S Young
Jun 29, 1995·Biochemical Pharmacology·A G EliopoulosD A Spandidos
Jan 1, 1995·British Journal of Haematology·D HiletiA V Hoffbrand
Aug 15, 1994·FEBS Letters·K FukuchiK Gomi

❮ Previous
Next ❯

Citations

Jul 12, 2002·The Journal of Biological Chemistry·Holly BowenC Howard Barton
Sep 20, 2007·Cell Proliferation·S G BerrakE Eksioglu-Demiralp
Dec 22, 1999·American Journal of Hematology·D S KyriakouG D Eliopoulos
Nov 5, 1999·Carcinogenesis·K Kramer-SticklandG T Bowden
Dec 27, 2005·Cancer Investigation·Paula M B Pahl, Lawrence D Horwitz
Jun 16, 2001·Journal of Cellular Biochemistry·K MacleanJ L Cleveland
Apr 28, 2005·Molecular & Cellular Proteomics : MCP·Zizheng DongJian-Ting Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis